| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8770829 | The Journal of Urology | 2018 | 7 Pages |
Abstract
In our retrospective cohort of patients with locally advanced bladder cancer dose dense MVAC was associated with higher complete pathological response and improved survival rates compared to gemcitabine and cisplatin. A clinical trial is warranted to validate these hypothesis generating results to test the superiority of neoadjuvant dose dense MVAC in patients with locally advanced bladder cancer.
Keywords
TURBTmethotrexate, vinblastine, doxorubicin and cisplatinMVACgemcitabine and cisplatinSWOGPPRCSSNACLVITransurethral resection of bladder tumorCancer specific survivaloverall survivalLymph node invasionGemcitabineUrinary bladder neoplasmscisplatinRadical cystectomyNeoadjuvant chemotherapyMortalityPCRcomplete pathological responseSouthwest Oncology Group
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Homayoun Zargar, Jay B. Shah, Bas W. van Rhijn, Siamak Daneshmand, Trinity J. Bivalacqua, Philippe E. Spiess, Peter C. Black, Wassim Kassouf,